Tuberculosis (TB) drug resistance, particularly multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), is a major global health challenge. It occurs when Mycobacterium tuberculosis no longer responds to first-line drugs like isoniazid and rifampicin, making treatment longer, costlier, and less effective. Drug-resistant TB increases morbidity and mortality, complicates public health efforts, and poses a serious threat to global infectious disease control. Early detection through molecular diagnostics, adherence to treatment, and development of novel therapeutics are critical in addressing this crisis.
In 2025, the global tuberculosis drug resistance market—including diagnostics, second-line therapies, and novel drug development—is valued at about USD 3.2 billion. With growing investments in rapid molecular testing, shorter treatment regimens, and global health initiatives, the market is projected to reach USD 5.6 billion by 2030, at a CAGR of 11.1%. High-burden regions such as Asia and Africa dominate demand due to elevated TB prevalence, while North America and Europe lead in R&D and funding for innovative treatment solutions. Expansion of public-private partnerships and WHO-backed initiatives will further drive market growth.
Share this page on your timeline
ALSO READ Infectious Diseases and Global Health Viral Infections Bacterial Infections Fungal Infections Vector-borne Diseases Virology and HIVAIDS Immunology and Clinical Microbiology Antiviral Drug Resistance Catheter-Associated Urinary Tract Infection Emerging Infectious Diseases Hospital-Acquired Infections HAIs Maternal-Fetal Infections Next-Generation Antibiotics Pediatric Infectious Diseases Sepsis Diagnosis and Care Zoonotic Diseases Neurological and CNS Infections Healthcare-Associated Infections Ophthalmological Infectious Diseases Lower Respiratory and Pediatric IDs Genomics and Infectious disease Special Session on COVID-19 Vaccines and Immunizations Antibiotic Sensitivity Testing Blood-Borne Disease Contagious Disease Encephalitis Global Pandemic Preparedness Influenza Surveillance Systems Microbiome and Immunity Occupational Safety and Health OSH Point-of-Care Testing POCT Travel-Related Infections Tropical Diseases and Parasitic Diseases Sexually Transmitted Diseases and STIs Pathophysiology and Diagnosis Clinical Trials and Case Studies Influencing Factors of IDs Advanced Treatments and Technologies Oral and Maxillofacial Infections Prevention and Control Public Health and Epidemiology Artificial Intelligence in ID Climate Change and Infections Gastroenteritis HIV and Co-Infections Malaria Elimination Strategies Neglected Tropical Diseases NTDs One Health Approach Rapid Diagnostic Innovations Tuberculosis Drug Resistance
Tags
Infectious Diseases Conferences Europe
Infectious Disease Conferences
HIV/AIDS Conferences
Epidemiology Conferences
Infection Conferences 2026 USA
Influenza Conferences
Infection Conferences 2027
Infectious Disease Conferences USA
Infectious Diseases Conferences
Infection Conferences 2027 Asia
Vector-Borne Diseases Conferences
Infection Conferences 2026 Europe
Infectious Disease Conferences 2026 Asia
Entomology Conferences